Crystal Pharmatech and Scientific Update Will Present Training Sessions and Seminars Targeting Pharmaceutical Development May 15-16, 2014

Share Article

Dr. Ann Newman, Ph.D., Dr. John Knight, Ph.D., Dr. Robert Wenslow, Ph.D. will address polymorphism, crystallization, amorphous materials and co-crystals in "How To Identify the Optimal Solid State Form for Pharmaceutical Development".

"This training session/seminar will focus on how to understand the properties of organic molecules as they relate to the solid state," explained Dr. Robert Wenslow, VP BD, Crystal Pharmatech.

Crystal Pharmatech, a leading contract research organization (CRO) for solid state research of active pharmaceutical ingredients (API’s) and formulations, announced today it is sponsoring a training session and seminar called “How to Identify the Optimal Solid State Form for Pharmaceutical Development” with Scientific Update, a leading conference organizer that targets industrial chemists and chemical engineers in chemical development and scale-up. The two day session will take place at Rutgers University, NJ, May 15-16, 2014. Participating in the training session are Dr. Ann Newman, Ph.D, Dr. Robert Wenslow, Ph.D, Dr. John Knight, Ph.D., each of whom will address different topics that focus on how to understand the properties of organic molecules as they relate to the solid state. Other industry-related topics include the fundamentals of amorphous materials, co-crystals and the control of crystallization.

As the scientific complexity of chemical development increases, finding the optimal development path for both drug substance (API) and drug product (formulation) is of utmost importance. This demands a fundamental understanding of the materials science surrounding the API and formulations. This course will provide bench level chemists, formulators, engineers and lawyers an in-depth understanding of the solid state as it applies to all aspects of pharmaceuticals.

Crystal Pharmatech is headquartered in Suzhou, China with US operations in Princeton, NJ and is a technology-driven CRO that offers materials research services for active pharmaceutical ingredients and formulations used in the drug discovery process. As a preferred provider among innovator pharmaceutical companies, Crystal Pharmatech has extensive experience selecting the appropriate solid phase of a wide range of compounds. It provides its customers with data derived from experiments and also partners with clients to ensure comprehensive solutions for their research needs using solid-state research, crystallization process development based on sound scientific understanding.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Isabelle Kellogg
Visit website